Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
Question
Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
Direct answer
A 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer improves probability-weighted peak sales for Genmab's wholly owned ADC pipeline. — bullish pressure on GMAB via valuation expansion via clinical derisking of wholly owned ADC candidate.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-04
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer”, revision 1, evidence through 2026-10-04. https://marketontology.com/catalysts/2026-10-04/genmab-rina-s-adc-delivers-45-9-response-rate-in-platinum-resistant-ovarian-canc-21f2cc
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| GMAB | ▲Bull | 1–5 days | valuation expansion via clinical derisking of wholly owned ADC candidate | 55 |
Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
A 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer improves probability-weighted peak sales for Genmab's wholly owned ADC pipeline. — bullish pressure on GMAB via valuation expansion via clinical derisking of wholly owned ADC candidate.
Rina-S demonstrated 45.9% ORR and 9.5 month median PFS in platinum-resistant ovarian cancer.
- SourceRina-S demonstrated 45.9% ORR and 9.5 month median PFS in platinum-resistant ovarian cancer.
- TransmissionA 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer improves probability-weighted peak sales for Genmab's wholly owned ADC pipeline.
- SummaryGenmab posted Phase 2 RAINFOL-01 data for Rina-S in platinum-resistant ovarian cancer. The antibody-drug conjugate achieved a 45.9% objective response rate. Median progression-free survival reached 9.5 months with 12.1 months duration of response.
- GMABDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- GMAB closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- GMAB price vs. pre-event level
- GMAB volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Genmab Announces Rinatabart Sesutecan Phase 2 Results · press_release · 2026-10-03
Related catalysts
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian CancerGMAB
- 2026-10-04Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFSGMAB
- 2026-10-04Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFSGMAB
- 2026-10-04Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trialGMAB
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.